Drug Profile
Cord blood stem cell therapy - CellPraxis
Latest Information Update: 26 Feb 2019
Price :
$50
*
At a glance
- Originator CellPraxis
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 26 Feb 2019 Discontinued - Phase-I/II for Amyotrophic lateral sclerosis in Brazil (IV)
- 31 Oct 2012 Phase-I/II clinical trials in Amyotrophic lateral sclerosis in Brazil (IV)